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incorporating a ruthenium-based radiosensitizer
for EGFR-targeted combination therapy in
oesophageal cancer cells†
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Irini Skaripa-Koukelli,a,b Sarah Able,a Jim A. Thomas, c Robert Carlisleb and
Katherine A. Vallis *a
Radiolabelled, drug-loaded nanoparticles may combine the theranostic properties of radionuclides, the
controlled release of chemotherapy and cancer cell targeting. Here, we report the preparation of poly
(lactic-co-glycolic acid) (PLGA) nanoparticles surface conjugated to DTPA-hEGF (DTPA = diethyl-
enetriaminepentaacetic acid, hEGF = human epidermal growth factor) and encapsulating the ruthenium-
based DNA replication inhibitor and radiosensitizer Ru(phen)2(tpphz)
2+ (phen = 1,10-phenanthroline,
tpphz = tetrapyridophenazine) Ru1. The functionalized PLGA surface incorporates the metal ion chelator
DTPA for radiolabelling and the targeting ligand for EGF receptor (EGFR). Nanoparticles radiolabelled with
111In are taken up preferentially by EGFR-overexpressing oesophageal cancer cells, where they exhibit
radiotoxicity through the generation of cellular DNA damage. Moreover, nanoparticle co-delivery of Ru1
alongside 111In results in decreased cell survival compared to single-agent formulations; an effect that
occurs through DNA damage enhancement and an additive relationship between 111In and Ru1.
Substantially decreased uptake and radiotoxicity of nanoparticles towards normal human fibroblasts and
oesophageal cancer cells with normal EGFR levels is observed. This work demonstrates nanoparticle co-
delivery of a therapeutic radionuclide plus a ruthenium-based radiosensitizer can achieve combinational
and targeted therapeutic effects in cancer cells that overexpress EGFR.
Introduction
Oesophageal cancer is an aggressive and highly lethal form of
cancer.1 Current non-surgical treatments are based on the use
of radiotherapy in combination with cisplatin DNA-damaging
chemotherapy, usually alongside the antimetabolite fluoro-
uracil (5FU). However, survival rates remain poor and attempts
to improve patient outcomes with alternative chemotherapy
have been unsuccessful.1 Advances in the identification of key
genetic and epigenetic alterations underlying the development
and progression of cancer have paved the way for targeted
therapy as an alternative to cytotoxic chemotherapy. A com-
monly proposed molecular target is epidermal growth factor
receptor (EGFR), a plasma membrane-bound receptor over-
expressed by >67% of oesophageal primary tumours.2 In
addition, EGFR overexpression correlates with poor patient
survival following chemoradiotherapy3 and radioresistance.4
Unfortunately, clinical trials of EGFR inhibitors have demon-
strated limited benefit to date.5 Hence, there remains an
urgent need to develop new therapeutics active towards EGFR-
overexpressing oesophageal cancers.
Nanoparticles surface labelled with radionuclides can
combine the therapeutic properties of ionizing radiation (IR)
with the controlled release of radiosensitizing chemotherapy.6–9
By employing targeting moieties designed to bind a cell-surface
receptor overexpressed by cancerous but not normal cells, this
may enhance delivery of the therapeutic combination to cancer
cells, boosting therapeutic efficiency.10 A potential advantage of
this strategy over external beam radiotherapy is that distant
metastases in addition to primary tumour(s) may be targeted.
Although the majority of clinical therapeutic radionuclide thera-
peutics are low LET (linear energy transfer) β-emitters (LET =
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0.1–1.0 keV μm−1),11 high LET Auger electrons (LET = 4–26
keV μm−1) emitted by radionuclides such as 111In are also of
interest in this context.12 The short range of Auger electrons
(<20 nm in biological media) means cellular internalisation is
paramount for radiotoxicity, thus providing Auger electron-emit-
ting radiotherapeutics with higher cell-specificity and reduced
“cross-fire” damage to adjacent healthy tissue in comparison to
long-range β-particles (range in tissue: 50 µm–1.0 cm).12 A clini-
cal example of an Auger therapeutic is 111In-DTPA-hEGF (DTPA =
diethylenetriaminepentaacetic acid, hEGF = human epidermal
growth factor), a radiopharmaceutical with high potency towards
breast cancer cells that overexpress EGFR that has undergone a
phase I clinical trial for the treatment of EGFR-positive breast
cancer.13–15 Auger emitters conjugated to nanoparticles have
also been explored for cancer cell targeting applications.16–23
The single-photon emission computed tomography (SPECT)
imaging capability of 111In provides a means of direct visualisa-
tion of nanoparticle accumulation in vivo, thereby indicating the
potential of 111In-conjugates as theranostics.22,23
The biocompatible and biodegradable polymer PLGA (poly
(lactic-co-glycolic acid)) has been employed to form nano-
particles for delivering a wide variety of drugs in vitro and in
pre-clinical experiments.24–29 As drug delivery candidates, the
anti-cancer properties of substitutionally inert ruthenium(II)
polypyridyl complexes (RPCs) have been gaining increasing
interest as alternatives to platinum-based therapeutics or
highly potent organics.30–32 In particular, RPCs that bind DNA
by metallo-intercalation rapidly stall DNA replication fork pro-
gression, activating DNA damage checkpoints and preventing
growth of highly proliferative cancer cells by cell-
cycle arrest.33,34 One complex, Ru(phen)2(tpphz)
2+ (phen =
1,10-phenanthroline, tpphz = tetrapyrido[3,2-a:2′,3′-c:3″,2″-h:2′′′,
3′′′-j]phenazine), Ru1, demonstrates potency comparable to
that of cisplatin towards oesophageal cancer cells but with
reduced cytotoxicity towards normal cells.34 Importantly, treat-
ment with Ru1 results in enhanced cancer cell sensitivity to
radiotoxic external beam IR, indicating RPCs that target DNA
replication may also function as radiosensitizers.33,34 However,
improving cancer cell specificity is highly desirable to maxi-
mise potential therapeutic outcomes and minimise damage to
healthy cells. Accordingly, work has investigated numerous
RPCs in nanoparticle or liposome formulations,35–43 where
their chemical stability, tuneable hydrophobicity and attractive
photophysical properties are advantageous properties for drug
delivery applications. To combine the therapeutic effects of IR
and the radiosensitizing properties of Ru1, in this study we
utilise PLGA nanoparticles to co-deliver 111In-labelled hEGF
and Ru1 to oesophageal cancer cells that overexpress EGFR,
demonstrating both a combinational effect and molecular tar-
geting for this novel therapeutic combination.
Results
Nanoparticle preparation and characterisation
PLGA nanoparticles encapsulating Ru1 and surface conjugated
to DTPA-hEGF were prepared (Scheme 1). This latter addition
provides both the targeting ligand for EGFR and DTPA chelat-
ing groups for subsequent 111In-radiolabelling. A double emul-
sion evaporation method was used for the preparation of
PLGA-Ru1 nanoparticles, where a drug-to-polymer ratio of
1 : 6.25 resulted in 11.4 μg Ru1 per mg nanoparticles; a drug
loading content (L.C.%) of 1.14. Transmission electron
microscopy (TEM) and dynamic light scattering (DLS) indi-
cated nanoparticles were spherical and approximately
130–140 nm in diameter (Fig. 1a and Table 1). TEM also con-
firmed Ru1-loading within the PLGA core, as direct visualisa-
tion of the complex due to the electron-dense ruthenium is
evident by this technique (Fig. 1a). DTPA-hEGF conjugated
nanoparticles (hereafter referred to as hEGF-PLGA) were pre-
pared by reacting PLGA nanoparticles with DTPA-hEGF
employing established EDC/NHS (EDC = 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide, NHS = N-hydroxysuccinimide) con-
jugation chemistry.44 This involves activation of the terminal
carboxyl groups of PLGA through an NHS-PLGA intermediate
before amide bond formation to DTPA-hEGF. A reaction ratio
of 1 μg hEGF : 200 µg PLGA resulted in a final ratio of 2 μg
hEGF per mg nanoparticles (Fig. S1 in the ESI†). Attachment
of hEGF to PLGA was examined by SDS-PAGE. This technique
relies on the principle that nanoparticles are unable to migrate
through the gel whereas the denaturing conditions of
SDS-PAGE breaks weak (non-covalent) bonds, thereby allowing
separation of any unattached or adsorbed peptide. PLGA nano-
particles were washed before loading to remove unreacted
Scheme 1 a) Radiolabelled nanoparticles employed in this study. The
ruthenium(II) metallo-intercalator and radiosensitizer, Ru1, is encapsu-
lated within a PLGA core and nanoparticles are surface labelled with
111In-DTPA-hEGF. PLGA = poly(lactic-co-glycolic acid, Ru1 = Ru
(phen)2(tpphz)
2+ (phen = 1,10-phenanthroline, tpphz = tetrapyrido[3,2-
a:2’,3’-c:3’’,2’’-h:2’’’,3’’’-j]phenazine), hEGF = human epidermal growth
factor, DTPA = diethylenetriaminepentaacetic acid. (b) Chemical struc-
ture of Ru1.
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hEGF. As shown in Fig. 1b, after electrophoretic separation,
the addition of the protein stain Coomassie blue revealed a
strong band at the top of the gel for PLGA reacted with hEGF
in an NHS/EDC-dependent manner. The absence of a band
corresponding to free hEGF protein at the bottom of the gel
(molecular weight approximately 6.4 kDa) is consistent with
the successful covalent conjugation of hEGF to PLGA and
removal of unbound hEGF by washing. In the control sample
which lacked NHS/EDC, no protein staining was seen at the
top of the gel, confirming an absence of covalent attachment
of hEGF to PLGA in this sample (Fig. 1b). The increase in
nanoparticle zeta potential after reacting with hEGF (Table 1)
is additionally consistent with successful surface-grafting of
the peptide to PLGA.44 Examination of particle size by DLS
over an extended period indicated nanoparticles were stable
>30 days in solution, with no evidence of aggregation in this
time frame (Table S1 and Fig. S2†). Encapsulated Ru1 dis-
played a biphasic release profile involving release of 46% of
the encapsulated Ru1 in 2 days and slower release of a further
27% of the encapsulated compound in the subsequent 12 days
(Fig. 1c). Radiolabelling of nanoparticles with 111InCl3
achieved a specific activity of 4–6 MBq 111In per mg
hEGF-PLGA and a radiochemical purity of >95% after removal
of unbound 111InCl3 (Fig. 1d). The absence of radiolabelling of
native PLGA-Ru1 particles confirmed DTPA-hEGF conjugation
is required for successful radiolabelling (Fig. S3†).
EGFR-mediated nanoparticle uptake
The conjugation of hEGF aimed to achieve increased levels of
nanoparticle uptake in oesophageal cancer cells that over-
express EGFR compared to cells with normal EGFR levels. First,
immunoblotting and densitometry were used to confirm rela-
tive EGFR expression in three different oesophageal cancer cell
lines. HFF-1 immortalised human foreskin fibroblasts were
included as a non-cancer derived cell line. These results show
the OE21 human oesophageal squamous cell carcinoma
(ESCC) cell line expresses substantially greater levels of EGFR
compared to either OE33 or FLO-1 human oesophageal adeno-
carcinoma cell lines (Fig. 2a). The number of EGFR receptors
per cell for each cancer cell line was quantified by 111In-DTPA-
hEGF competition binding assay and found to be 8.93 × 105,
6.16 × 104 and 4.76 × 103 receptors per cell for OE21, OE33 and
FLO-1 cells respectively. These EGFR expression results for the
three cell lines are in agreement with publicly available data
from the Cancer Cell Line Encyclopedia (CCLE).45 Next, the
uptake of radiolabelled nanoparticles in each cell line was
determined by quantifying total cell-associated radioactivity
(internalised and surface-bound). This revealed EGFR-over-
expressing OE21 cells demonstrated the greatest level of particle
accumulation of the four cell lines tested; an approximately
two-fold greater level of radioactivity than for either OE33 or
FLO-1 cells (Fig. 2b and Table S2†). The lowest levels of intern-
alisation were found in normal HFF-1 cells, correlating with
these cells demonstrating the lowest EGFR expression (Fig. 2a
and b). The similar level of nanoparticle uptake by OE33 and
FLO-1 cells is consistent with their comparable EGFR
expression. Compared to radiolabelled nanoparticle treatment,
substantially decreased levels of radioactivity were observed in
all four cell lines when treated with equivalent concentrations
Fig. 1 (a) TEM images of unloaded (left) and Ru1-containing (right)
PLGA nanoparticles. For unloaded PLGA nanoparticles (left) uranyl
acetate contrast stain was employed. For Ru1-loaded particles (right), no
TEM contrast stain was used, thereby allowing direct visualisation of Ru1
contrast within the PLGA core. (b) Coomassie blue stained SDS-PAGE
gel of free hEGF (1 μg, left lane) or PLGA nanoparticles (1 mg) added to
hEGF in the presence (middle lane) or absence (right lane) of NHS/EDC
crosslinking agents. Nanoparticles were separated from unreacted hEGF
by centrifugation before loading. *hEGF-PLGA, #hEGF. (c) Release kine-
tics of hEGF-PLGA-Ru1 showing biphasic release profile of Ru1. (d)
Representative instant thin layer chromatograms (iTLC) of purified
111In-hEGF-PLGA and 111In-hEGF-PLGA-Ru1 nanoparticles in citrate
buffer using EDTA (0.5 M, pH = 7.6) as the mobile phase.
Table 1 Physical properties of nanoparticles used in this study
Nanoparticles
Diameter
(nm)
Polydispersity
index
Zeta potential
(mV)
PLGA 129.0 0.178 −22.8
PLGA-Ru1 138.8 0.087 −12.1
hEGF-PLGA 136.1 0.051 −3.4
hEGF-PLGA-Ru1 133.0 0.236 −4.7
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of free 111InCl3, confirming nanoparticle-mediated uptake was
responsible for the majority of measured cellular radioactivity
(Fig. 2b, grey).
hEGF binding to EGFR results in autophosphorylation of
intracellular tyrosine residues of the receptor.46 Accordingly,
the level of EGFR phosphorylated at one such autophosphory-
lation site, Tyr1068, was examined to provide an indication of
successful EGF-EGFR binding. As shown in Fig. 2c, western
blot analysis revealed that, compared to an untreated control
sample, OE21 cells treated with hEGF-PLGA nanoparticles
showed a rapid increase in the level of EGFR phosphorylated
at Tyr1068 (pEGFR) with no change in total EGFR protein
content. In contrast, there was no increase in pEGFR level
above control in cells treated with non-hEGF conjugated PLGA
nanoparticles (Fig. 2c). Finally, pre-blocking OE21 cells with
non-radiolabelled hEGF before co-incubation of cells with
111In-labelled and hEGF-tagged particles resulted in a decrease
in intracellular radioactivity with increasing hEGF concen-
tration, where >80% of uptake was blocked at the highest con-
centration of hEGF employed (Fig. 2d). Together, these find-
ings are consistent with (i) EGFR binding and (ii) EGFR-
mediated cellular uptake of hEGF-PLGA nanoparticles.
Subcellular distribution of 111In and Ru1
The short range of Auger electrons in biological media means
cellular internalisation, and particularly nuclear uptake, is
desirable to achieve radiotoxicity.12 On examining the sub-
cellular distribution of internalised radioactivity in OE21 cells
after treatment with 111In-hEGF-PLGA (2 h), 111In was found to
have accumulated primarily in the cytosol with 5.1 ± 0.1% of
the total cell-internalised radioactivity detected within the
nuclear fractions (Fig. 3a and S4†). This subcellular distri-
bution remained unchanged following exposure for up to 24 h
(Fig. S5†). Similar subcellular distributions were obtained for
OE33 cells treated with 111In-hEGF-PLGA, albeit at lower total
cellular radioactivity due to reduced nanoparticle uptake in
this cell line (Fig. 3a and S4†). In comparison to the results for
hEGF-labelled nanoparticles, a greater level of total interna-
lised radioactivity (14.8 ± 3.8%) was located within isolated
nuclear fractions in cells treated with 111In-DTPA-hEGF
peptide (Fig. S6†), in agreement with previous work and the
nuclear translocation properties of EGFR.13,47
To assess Ru1 uptake and localisation, ruthenium content
of nanoparticle-treated cells was determined by inductively
coupled plasma mass spectroscopy (ICP-MS). This indicated
that the majority (>65%) of total intracellular Ru content was
detected in isolated nuclear fractions of cells treated with
Ru1-loaded nanoparticles after 24 h (Fig. 3b). These results
additionally indicated Ru content in nanoparticle-treated cells
was approximately 1.5-fold higher in OE21 cells compared to
OE33; a result in agreement with radioactivity data above
(Fig. 2b). Surprisingly, these results also indicated the amount
of Ru detected was lower than cells treated with an equivalent
concentration of free Ru1. This finding may be explained by
relatively low loading of Ru1 within PLGA, a common
outcome for hydrophilic compounds,24 and also different
uptake pathways: PLGA nanoparticles are thought to be inter-
nalised primarily by endocytosis48 while a non-endocytic
mechanism of active transport has been indicated for Ru1.49
Finally, as Ru1 is an metal to ligand charge transfer (MLCT)
“light switch” complex that demonstrates a large increase in
emission intensity when bound to DNA (ref. 49 and Fig. S7†),
we examined nanoparticle-treated cells by confocal laser
scanning microscopy. Applying this technique, luminescence
in the cell cytosol was visible along with clear evidence of
nuclear-localised Ru1 (Fig. 3c and Fig. S8†). Taken together,
these results show that the majority of the nanoparticles
themselves remain in the cell cytosol while the greater levels
of nuclear-targeting demonstrated by Ru1 compared to 111In
indicate the successful release of the complex from the
nanoparticles.
Fig. 2 (a) EGFR levels in HFF-1 normal human fibroblasts and OE21,
OE33 and FLO-1 oesophageal cancer cells, as determined by immuno-
blotting of whole-cell lysates with anti-EGFR antibodies (top) and quan-
tified by densitometry (bottom). Data expressed as a ratio of EGFR to
β-actin levels and are normalised to results for HFF-1 cells. Mean of two
technical repeats ± S.D. (b) Uptake of 111In-labelled hEGF-PLGA nano-
particles by HFF-1, OE21, OE33 or FLO-1 cells, as assessed by interna-
lised cellular radioactivity (2 h incubation). Data expressed as counts per
minute (CPM) per μg cell protein. Mean of triplicates ± S.D. Results for
each cell line treated with equivalent amounts of added radioactivity of
111InCl3 included for comparison (grey). (c) Western blot analysis of total
EGFR and pEGFR (EGFR phosphorylated at Tyr1068) levels in OE21 cell
lysates. Cells were serum-starved (24 h) before treatment with hEGF (50
ng mL−1), hEGF-PLGA (0.5 mg mL−1) or PLGA (0.5 mg mL−1) for 5 or
15 minutes. (d) Effect of EGFR blocking on 111In-hEGF-PLGA uptake in
OE21 cells. Cells were pre-incubated with a concentration range of
non-radiolabelled hEGF (1 h) before addition of 111In-hEGF-PLGA
(0.5 MBq mL−1) plus non-radiolabelled hEGF (2 h co-incubation). The
internalised radioactivity was measured and normalised to control (i.e.
unblocked) conditions. Data are the mean of two independent experi-
ments ± S.D., where each experiment was performed in triplicate.
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Nanoparticle impact on cell proliferation
Investigation of the impact of non-radiolabelled nanoparticles
on the cell viability of OE21 or OE33 cells by MTT assay
showed that Ru1-loaded hEGF-PLGA particles demonstrate
relatively mild cytotoxic effects due to the low loading of Ru1.
Despite this, it was evident that hEGF-PLGA particles showed
greatest cytotoxicity in EGFR-overexpressing OE21 cells, where
a greater impact on cell viability compared to either free
complex or non-targeted PLGA-Ru1 nanoparticles was achieved
(Fig. 4a and Table S4†). In comparison to OE21 cells,
hEGF-PLGA-Ru1 had a reduced impact on EGFR-normal OE33
cells, in which cell viabilities >70% compared to untreated
were obtained (Fig. 4a). In addition to these results employing
oesophageal cancer cell lines, decreased potency of
hEGF-PLGA-Ru1 toward HFF-1 normal human fibroblasts com-
pared to OE21 cells was seen, where cell viabilities remained at
>70% compared to untreated cells (Fig. 4b and Table S4†). No
obvious cytotoxicity of native (empty) PLGA nanoparticles was
observed (Fig. S9†).
Next, the effect of radiolabelled 111In-hEGF-PLGA nano-
particles on cell survival was measured by clonogenic survival
assay; the standard method to assess radiotoxicity as this pro-
vides a long-term measure of proliferation inhibition. OE21
and OE33 cell lines were selected as representative EGFR over-
expressing and EGFR normal cells, respectively. Cells were
treated in parallel with equivalent concentrations of non-
radiolabelled nanoparticles to evaluate the effect on cell survi-
val of incorporation of 111In into the nanoparticle construct.
These data indicated that treatment with 111In-labelled
hEGF-PLGA nanoparticles induced a substantial decrease in
clonogenic survival (surviving fractions, S.F., <0.2 relative to
untreated) in OE21 cells at specific activities of 1 MBq mL−1
and greater (Fig. 5a). Treatment with free 111InCl3 did not
impact cell proliferation up to the maximum concentration of
Fig. 3 (a) Sub-cellular radioactivity content of OE21 or OE33 cells
treated with 111In-hEGF-PLGA (0.125–0.5 MBq mL−1, 2 h). Isolated
cytosol (Cyt) and nuclear (Nuc) fractions were obtained. The amount of
accumulated radioactivity was measured by gamma-counting and nor-
malised to protein content of each fraction (experiment performed in
triplicate ± S.D.). See ESI† for verification of efficient sub-cellular frac-
tionation and data expressed as % of total radioactivity added. (b) Sub-
cellular ruthenium content of OE21 or OE33 cells treated with
hEGF-PLGA-Ru1 (1 mg mL−1, 24 h), as determined by ICP-MS. Data for
cells treated with equivalent concentration of free Ru1 (12 μM, 24 h)
included for comparison. Data are normalised to protein concentration
and are the mean of two independent experiments ± S.D. (c) Confocal
microscopy (CLSM) of OE21 or OE33 cells treated with hEGF-PLGA-Ru1
(1 mg mL−1, 24 h) showing intracellular MLCT (metal to ligand charge-
transfer) emission of Ru1. Live cell imaging (top row) or the same cells
visualised immediately after 4% formaldehyde fixation (bottom row).
Identical imaging parameters were used for all images shown. Arrows
indicate nuclear MLCT emission.
Fig. 4 (a) Impact of Ru1-containing hEGF-PLGA or PLGA nanoparticles
on cell viability of OE21 (overexpressed EGFR) or OE33 (normal
EGFR levels) oesophageal cancer cells. Cell viabilities determined by
MTT assay (24 h incubation) and expressed as a function of Ru1 concen-
tration. The equivalent concentration of free Ru1 is included for
comparison. (b) Impact of Ru1-containing nanoparticles on cell viability
of HFF-1 normal human fibroblasts. Data for (a,b) are the mean of two
or three independent experiments ± S.D, where each experiment was
performed in triplicate.
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4 MBq mL−1 (Fig. 5a), consistent with the principle that cellu-
lar internalisation of 111In is a requirement for radiotoxicity.13
Notably, the inclusion of Ru1 resulted in 111In-hEGF-PLGA-
Ru1 particles demonstrating two- to five-fold greater cyto-
toxicity than empty 111In-hEGF-PLGA (Fig. 5a and Table S5†).
The highest concentration of empty hEGF-PLGA nanoparticles
(1 mg mL−1) was found to have a minor impact on OE21 cell
survival, likely due to the cytotoxic effects of hEGF peptide
towards EGFR-overexpressing cells.50 By comparison to data
for single-agent nanoparticle formulations hEGF-PLGA-Ru1
and 111In-hEGF-PLGA, the overall impact of 111In-hEGF-PLGA-
Ru1 on OE21 cell survival indicates an additive contribution
from both 111In surface-labelling and the inclusion of Ru1
within the nanoparticles (Table S5 and Fig. S10†). 111In-
hEGF-PLGA showed low radiotoxicity towards normal EGFR
OE33 cells (S.F.s > 0.66) while 111In-hEGF-PLGA-Ru1 nano-
particles were substantially less toxic than parallel results for
OE21 cells, where an approximately 45-fold greater activity
towards EGFR overexpressing cells at the highest dose of
111In-hEGF-PLGA-Ru1 was observed (Fig. 5a and Table S5†).
Due to their inability to form colonies, HFF-1 cells were
incompatible with clonogenic survival assays, however, assess-
ment of cell viability by MTT assay showed reduced radiotoxi-
city of radiolabelled nanoparticles towards HFF-1 normal
fibroblasts compared to OE21 cells (Fig. S11†). These results
are in agreement with the 111In-labelled hEGF-PLGA nano-
particles demonstrating increased radiotoxicity towards cells
that overexpress EGFR compared to cells that express normal
levels of the receptor and additionally show that cytotoxicity
may be further enhanced by inclusion of Ru1.
Nanoparticle-induced DNA damage
Auger electron radiotherapeutics are able to induce DNA
damage if in close proximity to the cell nucleus14 while the
Fig. 5 (a) Clonogenic survival assays of OE21 or OE33 cells exposed to 111In radiolabelled hEGF-PLGA nanoparticles with or without Ru1-loading
(24 h incubation time). Non-radiolabelled nanoparticles (in equivalent concentrations; 0–1000 μg mL−1) and free 111InCl3 (in equivalent specific
activity) are included as controls. Data points are the mean of triplicates ± S.D. (b) Representative CLSM images of OE21 or OE33 cells treated with
111In-hEGF-PLGA-Ru1 (2 MBq mL−1, 24 h) followed by immunofluorescence staining for γH2AX (green). DNA was counterstained with DAPI (blue).
See ESI† for full micrographs. (c) Quantification of γH2AX foci/nucleus (in plane of view) for cells treated as in (b). Data are the average of two inde-
pendent experiments ± SD. A minimum of 100 nuclei were counted for each treatment group. (d) Immunoblotting of OE21 or OE33 whole-cell
lysates for γH2AX expression after treatment with 111In-hEGF-PLGA or 111In-hEGF-PLGA-Ru1 (2 MBq mL−1, 24 h). β-Actin was used as a loading
control. Cells treated with free 111InCl3 (specific activity equivalent) were included for comparison.
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radiosensitizing effects of Ru1 for 137Cs γ-rays have been
shown to occur through DNA damage enhancement.34
Accordingly, DNA damage generated as a result of radio-
labelled nanoparticle exposure was examined. Treatment of
cells with 111In-hEGF-PLGA-Ru1 (2 MBq mL−1, 24 h) resulted
in increased levels of the DNA damage marker γH2AX in OE21
cells compared to an untreated control sample (Fig. 5b and c).
This result was supported by immunoblotting for γH2AX
expression in lysates prepared from 111In-hEGF-PLGA- or 111In-
hEGF-PLGA-Ru1-treated OE21 cells (Fig. 5d). A minimal
increase in γH2AX levels was observed in EGFR normal OE33
cells treated with radiolabelled nanoparticles and also when
either cell line was treated with free 111InCl3 (Fig. 5b–d); find-
ings consistent with nanoparticle-mediated 111In uptake being
responsible for the observed DNA damage.
To assess the individual contributions of 111In and Ru1 to
DNA damage generation, single- or dual-agent nanoparticle
formulations were prepared and levels of γH2AX foci in cells
treated with equivalent doses were elucidated. These results
indicated that the level of γH2AX foci is greatest for the nano-
particle formulation that contains both 111In and Ru1
(Fig. 6a). Moreover, quantification of γH2AX foci/nucleus indi-
cates DNA damage induced by 111In-hEGF-PLGA-Ru1 equates
to the sum of that caused by the individual single-agent nano-
particle treatment conditions, hEGF-PLGA-Ru1 and 111In-
hEGF-PLGA (Fig. 6b). In addition to increased γH2AX levels,
treatment of OE21 cells with 111In-hEGF-PLGA or 111In-
hEGF-PLGA-Ru1 (1 MBq mL−1, 24 h) resulted in marked induc-
tion of phospho-Chk2 (Thr68), while the appearance of
phospho-Chk1 (Ser345) was also observed (Fig. 6c). These cel-
lular responses indicate that nanoparticle-conjugated 111In
activates both double-strand break (DSB) damage and single-
strand break (SSB) DNA damage response (DDR) signalling
after successful cellular internalisation, in agreement with
Auger electrons inducing both forms of DNA lesion.14
Together, these findings indicate that dual delivery of Ru1 and
111In results in enhanced DNA damage in oesophageal cancer
cells that overexpress EGFR and are consistent with an additive
therapeutic relationship between Ru1 and 111In.
Nanoparticle biodistribution
One aspect of the proposed therapeutic use of nanoparticles is
the ability of nanoparticles to target tumours in vivo. Gamma-
radiation emitted by 111In may provide detailed biodistribution
Fig. 6 (a) CLSM images of OE21 cells treated with 111In-hEGF-PLGA or 111In-hEGF-PLGA-Ru1 (1 MBq mL−1, 24 h) followed by immunofluorescence
staining for γH2AX (green). DNAwas stained with DAPI (blue). Equivalent non-radiolabelled hEGF-PLGA-Ru1 treatment was included for comparison.
(b) Quantification of γH2AX foci/nucleus (in plane of view) for cells treated as in (a). Data average of two independent repeats ± S.D. A minimum of
100 nuclei per condition were counted. (c) Immunoblotting of OE21 whole-cell extracts after 24 h treatment with non-radiolabelled hEGF-PLGA-
Ru1, 111In-hEGF-PLGA or 111In-hEGF-PLGA-Ru1 (1 MBq mL−1) using anti-pChk2 (Thr68) or pChk1 (Ser345) antibodies, as indicated. Total Chk2 and
Chk1 protein content is provided. β-Actin was used as a loading control. Cells treated with free 111InCl3 (specific activity equivalent) or free Ru1 (con-
centration equivalent) were included for comparison.
Paper Nanoscale
10602 | Nanoscale, 2018, 10, 10596–10608 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
9 
M
ay
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
/2
4/
20
20
 1
1:
02
:5
7 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
information to assess tumour accumulation of 111In-radio-
labelled nanoparticles.23 Accordingly biodistribution of 111In-
labelled hEGF-PLGA nanoparticles was examined. 111In-
hEGF-PLGA or 111In-hEGF-PLGA-Ru1 nanoparticles were admi-
nistered to mice bearing oesophageal tumour xenografts by
intravenous injection and the resultant biodistribution deter-
mined by quantifying radioactivity in organs. OE21 cells were
used as a representative EGFR-overexpressing cell line for gene-
ration of xenografts. Following sub-cutaneous inoculation of
OE33 cells in BALB/c Nu/Nu mice, xenograft tumours grew very
slowly, consistent with the reported experience of others.51
FLO-1 cells were therefore used as a representative cell line
with normal EGFR expression for generation of xenografts. At
24 h post-injection of 111In-hEGF-PLGA or 111In-hEGF-PLGA-
Ru1, uptake of radioactivity into the liver, spleen and kidneys
was prominent. Tumour uptake represented 0.6–1% of total
injected dose per gram (I.D. per g) with a tumour-to-muscle
(T/M) ratio in the range of 2.5–4 (Fig. S12 and S13†). There was
no significant difference in the level of tumour-associated
radioactivity or T/M ratios between OE21 and FLO-1 xenograft
models (Fig. S12 and S13†).
Discussion
Targeted combination therapy using functionalised nano-
particles with multiple therapeutic components and mecha-
nisms-of-action may achieve high cell specificity and act to
combat the common problem of drug-resistance.10,52 By devel-
oping radionuclide-labelled nanoparticles that encapsulate
complementary small molecule(s), these principles can also be
applied to the highly successful strategy of chemoradiotherapy
with the substantial added benefit of cell-specific targeting.
However, while utilising radiosensitizers alongside β-emitting
radiopharmaceuticals has made appreciable progress in the
clinic,11 combination therapy utilising Auger electron radio-
therapeutics remains under-developed.
The potential for using nanoparticles to deliver Auger elec-
tron radiotherapy has been demonstrated in studies conducted
by the Reilly and Allen groups.16–20 For example, block copoly-
mer micelles of ∼30 nm diameter surface-labelled with trastu-
zumab (Tz) were used to target 111In to Her2-positive breast
cancer cells.20 Although DNA damage was not investigated,
these investigators showed that radiotoxicity could be
enhanced by increasing nuclear targeting of 111In by addition
of a nuclear localisation signal to Tz (with ∼8% of total inter-
nalised radioactivity accumulating in cell nuclei). Moreover,
the inclusion of low dose methotrexate, a dihydrofolate
reductase inhibitor and potent radiosensitiser, significantly
enhanced cell killing. Similar to block copolymer micelles
developed by Fonge et al.19 and our previous work employing
111In-hEGF-labelled gold nanoparticles,21,22 111In-hEGF-PLGA
nanoparticles described in the current study demonstrate sub-
stantial radiotoxicity towards p53-deficient EGFR-overexpres-
sing cancer cells. Notably, radiotoxicity occurs with clear evi-
dence of DNA damage induction, observable by strong acti-
vation of DDR signalling, despite the modest extent of nuclear
localisation of 111In.
The discovery that RPCs may function as radiosensitizers
for cancer cells has extended their potential therapeutic appli-
cation to include combination with IR. Although RPCs have
been examined as photosensitizers in nanoparticle formu-
lation,53,54 the requirement for simultaneous light exposure
and efficient delivery of nanoparticles to target cells for
effective phototoxicity presents challenges. Given the restricted
penetration of light in tissue, and limited options for localised
light delivery at present, this approach is only suitable for
superficial tumours. In contrast, a nanoparticle that combines
a radiosensitizer and radionuclide can achieve concomitant
co-delivery to a specified cell population in a primary tumour,
distant metastases or both. To validate the dual delivery
concept at the cellular level, the DNA replication inhibitor Ru1
– the most potent RPC radiosensitizer described to date – plus
111In were included in dual-agent hEGF-PLGA targeted nano-
particles. This agent resulted in an additive increase in cyto-
toxicity in oesophageal cancer cells that overexpress EGFR. The
additive increase in DNA damage with the inclusion of 111In
and Ru1 indicates a complimentary relationship between the
two DNA-damaging components. These data are the first dem-
onstration of an RPC and radionuclide being employed
together in such a manner. Slow-release PLGA nanoparticles
delivered a modest level of intracellular Ru1 but was nonethe-
less efficacious, illustrating the potential of combining a radio-
sensitizer at low dose with high linear energy transfer (LET)
Auger-emitting radionuclides via targeted nanoparticle deliv-
ery. The substantially reduced impact of 111In-hEGF-PLGA-Ru1
on EGFR normal cells represents a greater degree of cell-speci-
ficity than obtained for free Ru1 in the same cell lines34 and
indicates how this nanoparticle formulation may achieve mole-
cular targeting as well as concomitant co-delivery.
The synthetic preparation is ‘modular’ such that every com-
ponent – loaded drug, targeting peptide and radionuclide –
may be varied to account for the molecular characteristics of a
specific cancer. A key strength of this approach is that the
radionuclide labelling is the final step, minimising loss during
synthesis due to decay. However, as indicated in preliminary
studies presented here, relatively low accumulation of nano-
particles themselves is a common finding in solid tumours
in vivo after intravenous injection.55 This may be seen in seminal
work by Farokhzad and colleagues, where only 0.83% I.D.
(injected dose) of PSMA-targeted PLGA nanoparticles localised
to tumours in murine models.27 Indeed, a recent meta-analysis
of over 270 publications demonstrated that the “enhanced per-
meability and retention (EPR)” effect provides an average
passive accumulation level of 0.7% I.D. per g.55 Biodistribution
studies have also indicated that high liver and spleen accumu-
lation is a consequence of administering nanoparticles of this
shape and size by the intravenous route.55,56 Despite this low
tumour uptake, formulations based on polymeric nano-
particles that incorporate docetaxel have progressed to phase I
and II clinical trials for patients with metastatic prostate
cancer57,58 and several polymer-based nanoparticles are FDA-
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approved.59 It is also notable that the primary effect of adding
targeting ligands on nanoparticles may well be to improve cel-
lular internalisation rather than overall tumour accumu-
lation.10 This may be evidenced in studies using 111In-labelled
PSMA-targeted PLA (polylactic acid) nanoparticles where only
a modest increase in tumour I.D. per g was found for targeted
nanoparticles compared to non-targeted analogues.23 These
observations support our strategy of using short-range Auger
electron-emitting radionuclides, as their cellular uptake
requirements for radiotoxicity means non-specific organ
toxicity will be better controlled compared to long-range β par-
ticles. Finally, the combination is unlikely to be restricted to
PLGA nanoparticles and recent advances in nanoparticle
design56 or stimuli-based release mechanisms60 may further
extend the combination of Auger electron-emitting radio-
pharmaceuticals and DNA-targeting radiosensitizers. Future
work will aim to expand on these concepts.
Experimental
Chemicals
Ru1 was prepared using methods described by Bolger, et al.61
All NMR, mass spectroscopy and elemental analysis were in
agreement with published data. Unless stated otherwise, all
other chemicals were obtained from Sigma. Antibodies:
p-Chk1 (Ser345) and p-Chk2 (Thr68) (Cell Signaling), γH2AX
(Millipore), total Chk1 (Santa Cruz), total Chk2, α-tubulin
(both Abcam) and β-actin (Sigma). AlexaFluor488-conjugated
anti-mouse secondary antibodies were from Cell Signaling.
DTPA-hEGF was prepared as reported previously.62
Nanoparticle preparation
PLGA nanoparticles were prepared by a standard procedure.63
For preparation of PLGA-Ru1 nanoparticles, a double emulsion
evaporation method was employed where aqueous Ru1
(2.4 mg of Ru1 in 200 µL DI water) was added to 0.75% w/v
PLGA solution in chloroform. Following sonication for 1 min,
this emulsion was added dropwise to 4 mL of 5% w/v polyvinyl
alcohol (PVA). This suspension was then sonicated for 3 min
(VibraCell VCX130, 60% amplitude, three cycles of 55 s on, 5 s
off over ice) and stirred overnight. PLGA-Ru1 or PLGA particles
were collected by centrifugation (25 000 rpm for 40 min at
4 °C). For protein conjugation, particles (10 mg) were activated
with NHS (N-hydroxysuccinimide, 60 mg) and EDC (ethyl(di-
methylaminopropyl) carbodiimide, 72 mg) in MES buffer
(0.1 M, pH 4.9) with shaking for 30 minutes at room tempera-
ture before the addition of hEGF-DTPA (20 μg) overnight.
Conjugated nanoparticles were separated from unreacted
DTPA-hEGF by centrifugation at 25 000 rpm for 40 minutes at
4 °C using a Beckman Coulter optima max ultracentrifuge.
The amount of DTPA-hEGF present on the particles was deter-
mined using a Human EGF Quantikine ELISA kit (R&D
Systems, Inc., Minneapolis, MN, USA) following the manufac-
turer’s instructions.
Nanoparticle characterisation
The relative hydrodynamic diameter of nanoparticles was
determined by dynamic light scattering (DLS) using a Zetasizer
Nano ZS instrument (Malvern Instruments). Zeta potential
measurements were carried out using a disposable folded
capillary Zeta cell filled with the nanoparticle suspension in
deionised water at 20 °C according to the manufacturer’s
instructions. Zeta potential was calculated from the electro-
phoretic mobility of nanoparticles using the Smoluchowski
approximation. For TEM, samples were prepared by air-drying
0.01 mg mL−1 nanoparticle solution on a 200-mesh Formvar-
coated copper grid (Agar Scientific, Stansted, Essex, UK).
Empty PLGA nanoparticles were negatively stained with 2%
uranyl acetate. Nanoparticles were visualised on an FEI Tecnai
T12 electron microscope. Drug loading efficiency was deter-
mined by absorption spectroscopy at 450 nm with reference to
a standard curve of free drug absorbance/concentration. The
release of Ru1 from PLGA was evaluated by dispersing the par-
ticles (1 mg mL−1) in PBS and incubating them at 37 °C. At
predetermined timepoints, the particles were centrifuged
using a 10 000 MWCO filter for 10 min at 14 000 rpm. The
supernatant was collected for analysis and the particles were
re-dispersed in PBS before incubating them at 37 °C.
Absorbance readings of the supernatant were performed at
450 nm to determine Ru1 concentration. Excitation/emission
spectra of Ru1-loaded nanoparticles was recorded by TECAN
Infinite 200 PRO plate reader (excitation wavelength = 488 nm,
emission wavelength = 630 nm). To confirm DTPA-hEGF conju-
gation, purified conjugated nanoparticles were loaded on
NuPAGE® 4–12% Bis-Tris gels (1–2 mg nanoparticle per well)
alongside free DTPA-hEGF protein (1–5 μg per lane). Gels were
run in MES/TRIS/SDS running buffer, washed in water before
staining with SimplyBlue™ SafeStain (Thermo) overnight. Gels
were washed in water for 1–3 h to decrease background before
visualisation on an HP ScanJet 5590 Digital Flatbed Scanner.
Radiolabelling
111In labelled hEGF-PLGA nanoparticles were prepared by
mixing 111InCl3 in 0.1 M sodium citrate buffer (pH = 5.5) with
hEGF-PLGA or hEGF-PLGA-Ru1 at 4 °C for 1 h. A ratio of 10
MBq 111In per mg nanoparticles (equivalent to 10 MBq per μg
surface-conjugated hEGF) achieved approximately 40–60%
nanoparticle-bound 111In, corresponding to a specific activity of
4–6 MBq 111In per mg hEGF-PLGA. Radiolabelled nanoparticles
were separated from unbound 111In by centrifugation (13 000
rpm, 30 min) and the pellet resuspended in PBS before use.
Radiochemical purity was evaluated using instant thin layer
chromatography (iTLC, Eckert & Ziegler AR-2000 radio-TLC
Imaging Scanner) on glass microfiber chromatography paper
silicic acid with 0.5 M EDTA (pH = 7.6) as the mobile phase.
Radiochemical purity of >95% was required for all experiments.
Cell lines
OE21 human oesophageal squamous cell carcinoma,
OE33 human adenocarcinoma cells and FLO-1 distal oesopha-
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geal adenocarcinoma cells were a generous gift from
E. Hammond, Oxford University. OE21 and OE33 cells were
cultured in RPMI cell media supplemented with 10% FBS and
penicillin/streptomycin. FLO-1 were cultured in DMEM sup-
plemented with 10% FBS and penicillin/streptomycin. HFF-1
cells were cultured in DMEM supplemented with 15% FBS and
penicillin/streptomycin. Cell lines were maintained at 37 °C in
an atmosphere of 5% CO2 and sub-cultured by trypsin. Cell
lines were used at passage numbers 30 or lower and checked
to be mycoplasma-free on a monthly basis. Stock solutions of
Ru1 as the dichloride salt (2 mM) were prepared in PBS before
dilution in cell media. Cells treated with Ru1 were shielded
from light to minimise phototoxicity.
EGF receptor density
OE21, OE33 and FLO-1 cells were seeded at 5000 cells per well
and incubated overnight at 37 °C. The cells were then incu-
bated with 8 nM of 111In-DTPA-hEGF with varying concen-
trations of unlabelled hEGF (0 to 1000 nM) to block EGFR and
measure non-specific binding. Following incubation for 2 h,
the cells were washed twice with PBS and treated with 0.1 M
NaOH. Lysates were transferred to counting tubes for measure-
ment of radioactivity using the WIZARD-2 Automatic Gamma
counter (PerkinElmer). Cell protein was determined by BCA
assay to calculate the specific binding of radioactivity per mg
of cell protein. IC50 values were determined by GraphPad
Prism (GraphPad, SanDiego, CA) and used to calculate the
maximum number of receptors per cell (Bmax).
Cellular uptake studies
For total cellular uptake of radiolabelled nanoparticles, cells
were seeded in well plates and allowed to proliferate for 24 h.
Cells were incubated with a concentration-gradient of radio-
labelled nanoparticles, the radioactive cell media removed,
and cells washed twice with PBS before being lysed in radio-
immunoprecipitation assay (RIPA) buffer. Lysates were
collected by pipette and radioactivity measured by WIZARD-2
Automatic Gamma Counter. Readings were normalised to the
protein content for each sample, as determined by BCA assay.
For subcellular fractionation, the Nuclei EZ Lysis kit (Sigma)
was employed using a protocol adapted from Hoang et al.20
Briefly, OE21 or OE33 cells were treated in 12 well plates,
washed with cold PBS (2 × 2 mL) before washing with acidified
PBS (pH 2.5) to remove the surface-bound fraction. Next,
0.4 mL EZ lysis buffer was added, cells were detached by scrap-
ing, collected into eppendorf tubes, vortexed briefly and left
for 5 minutes on ice. Samples were centrifuged (500 g, 5 min)
and the supernatant (cytosol fraction) aspirated. The pellet
(nuclear fraction) was re-suspended in 200 μl RIPA buffer.
Successful fractionation of the two subcellular compartments
was verified by immunoblotting using anti-α-tubulin (Sigma)
and anti-histone H2AZ (Abcam) for cytosol and nuclear frac-
tions, respectively (Fig. S5b†). Radioactivity was measured
using a WIZARD-2 Automatic Gamma Counter. For ruthenium
content, OE21 or OE33 cells were treated in 12 well plates,
washed twice with cold PBS (2 mL) and nuclear and cytosol
fractions obtained using the Nuclei EZ Lysis kit (Sigma), as
described above. ICP-MS analysis was carried out as previously
reported.33 Counts per minute or Ru content of isolated frac-
tions were divided by protein content, as determined by BCA
assay.
MTT assay
Cells were seeded in 96 well plates (10 000 cells per well) and
allowed to adhere for 24 h. Cells were treated with 0–1000
μg mL−1 nanoparticle solutions (or the equivalent concen-
tration of free Ru1) for 24 h. After incubation, 0.5 mg mL−1
MTT (thiazolyl blue tetrazolium bromide) dissolved in serum-
free medium was added for 60 minutes and the formazan
product eluted using acidified isopropanol. Absorbance at
540 nm was quantified by plate reader (reference wavelength
650 nm) and the metabolic activity of cell populations was
determined as a percentage of a negative (solvent) control.
Clonogenic survival assay
OE21 or OE33 cells were seeded in 12 well plates, allowed to
adhere for 24 h and incubated with unlabelled or radio-
labelled Na2VO4 nanoparticles for 24 h. Cells were detached
using trypsin and re-seeded in 6 well plates at a density of
300–2000 cells per well (in triplicate). Cells were incubated
for 7–14 days after re-seeding to allow colony formation
before being fixed with 10% methanol, 10% acetic acid and
stained with 0.4% methylene blue. OE33 cells required an
additional formaldehyde fixation (4% in PBS, 5 min) step
before staining to prevent colony detachment. Colonies con-
taining 50 cells or greater were counted using a Gelcount
instrument and accompanying software (Oxford Optronix).
Plating efficiencies were determined for each treatment con-
dition and normalised to an untreated control to provide the
survival fraction (S. F.).
Microscopy and immunofluorescence
Cells were seeded on Ibidi 35 mm μ-dishes (Thistle Scientific)
and allowed to adhere for 24 h before treatment. Live cell
imaging conditions maintained cells at 37 °C and 5% CO2 for
the duration of the experiment. For fixed cell imaging, cell
media was removed, cells washed with PBS and fixed with for-
maldehyde (4%, 10 min). For immunofluorescence, cells were
permeablised with Triton (0.5% in PBS, 5 min) and washed
with PBS. Samples were blocked with BSA (3% in PBS-T) for
1 h before incubation with primary antibody (γH2AX, 1/250
dilution) in BSA (3% in PBS-T) for 1 h. Samples were washed 3
times in PBS-T and incubated with AlexaFluor488-conjugated
anti-mouse secondary antibodies (3% BSA in PBS-T, 1 h, 1/250
dilution). After washing three times (5 min PBS-T), samples
were co-stained with DAPI (5 ng mL−1, 2 min) and fresh PBS
added. Samples were visualised using a Zeiss LSM 780 inverted
confocal microscope and an EC Plan-Neofluar 40×/1.30 Oil
objective. DAPI, AlexaFluor488 and Ru1 emission signals were
collected as reported in a recent publication.34 γH2AX foci
were counted using ImageJ software and the number of nuclei
counted manually.
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Western blotting
After treatment, samples were washed with cold PBS and lysed
in RIPA buffer containing protease inhibitors (10 μg mL−1
leupeptin, 2 μg mL−1 pepstatin, 50 μg mL−1 antipain,
2 μg mL−1 aprotinin, 20 μg mL−1 chyprostatin, 2 μg mL−1 benz-
amidine, 1 mM phenylmethanesulfonyl fluoride) and phospha-
tase inhibitors (50 mM NaF, 1 mM Na3VO4 and 20 mM
β-glycerophosphate). Protein content was determined by BCA
assay. Aliquots of cell lysates (10–50 μg total protein) were
prepared in standard Laemmli buffer, heated at 95 °C for
5 minutes and resolved by NuPAGE® 4–12% Bis-Tris gels and
LDS-PAGE. Gels were transferred onto nitrocellulose mem-
brane and probed with primary antibodies in 5% BSA (bovine
serum albumin). Reactions were visualised with a suitable
secondary antibody conjugated with horseradish peroxidase
(1/5000 dilution, Thermo). Pierce ECL (Thermo) or
WesternSurePREMIUM (Li-Cor) chemiluminescent substrates
with X-ray development (Fuji medical film and Optimax 2010
processor) or digital analysis (LiCor C-Digit Blot Scanner) were
used to visualise protein expression.
Animal models
Animal procedures were carried out in accordance with the UK
Animals (Scientific Procedures) Act 1986 and with local ethical
committee approval. OE21 or FLO1 tumours were established
by subcutaneous injection of 2 × 106 cells suspended in 200 μL
1 : 1 RPMI : Matrigel into the right dorsal flank of female
BALB/c Nu/Nu mice. When tumours reached a size of approxi-
mately 8 mm geometric mean diameter (GMD), mice were
assigned randomly into treatment groups (3 or 4 mice per
group) and 111In-labelled nanoparticles (0.1 mg, 0.4 MBq,
5 mg kg−1) were administered by intravenous injection. At 24 h
post injection (p.i.), mice were euthanised and organs were
removed, weighed, and counted for radioactivity using a
WIZARD-2 Automatic Gamma Counter.
Conclusions
In summary, we demonstrate hEGF-PLGA nanoparticles can be
utilised to combine the therapeutic effects of an Auger electron-
emitting radionuclide, the controlled release of a radiosensitiz-
ing small molecule and cell receptor targeting. By using
111In-DTPA-hEGF and the ruthenium-based replication inhibitor
[Ru(phen)2(tpphz)]
2+ (Ru1), we show how co-delivery results in a
substantially greater decrease in cell survival in EGFR-overexpres-
sing oesophageal cancer cells compared to cells with normal
EGFR expression. Finally, by comparison to single-agent formu-
lations, we demonstrate this outcome is the result of an additive
increase of DNA damage generated by 111In and Ru1, thereby
verifying the nanoparticle-mediated therapeutic combination of
an Auger electron emitter and DNA-targeting radiosensitizer.
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